Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Debt to Equity: 2020-2023

Historic Debt to Equity for Mirum Pharmaceuticals (MIRM) over the last 2 years, with Mar 2023 value amounting to $0.01.

  • Mirum Pharmaceuticals' Debt to Equity fell 57.86% to $0.01 in Q1 2023 from the same period last year, while for Mar 2023 it was $0.01, marking a year-over-year decrease of 57.86%. This contributed to the annual value of $0.01 for FY2022, which is 53.78% down from last year.
  • As of Q1 2023, Mirum Pharmaceuticals' Debt to Equity stood at $0.01, which was up 0.63% from $0.01 recorded in Q4 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Debt to Equity peaked at $0.02 during Q2 2021, and registered a low of $0.01 during Q1 2021.
  • In the last 3 years, Mirum Pharmaceuticals' Debt to Equity had a median value of $0.02 in 2021 and averaged $0.01.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Debt to Equity soared by 163.78% in 2022, and later crashed by 57.86% in 2023.
  • Over the past 4 years, Mirum Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.01 in 2020, then skyrocketed by 126.07% to $0.02 in 2021, then crashed by 53.78% to $0.01 in 2022, then slumped by 57.86% to $0.01 in 2023.
  • Its Debt to Equity stands at $0.01 for Q1 2023, versus $0.01 for Q4 2022 and $0.01 for Q3 2022.